GYRE THERAPEUTICS INC (GYRE) Fundamental Analysis & Valuation

NASDAQ:GYRE • US4037831033

Current stock price

7.5 USD
-0.05 (-0.73%)
At close:
7.5 USD
0 (0%)
After Hours:

This GYRE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. GYRE Profitability Analysis

1.1 Basic Checks

  • GYRE had positive earnings in the past year.
  • GYRE had a positive operating cash flow in the past year.
  • GYRE had negative earnings in 4 of the past 5 years.
  • In the past 5 years GYRE reported 4 times negative operating cash flow.
GYRE Yearly Net Income VS EBIT VS OCF VS FCFGYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 4.17%, GYRE belongs to the top of the industry, outperforming 90.35% of the companies in the same industry.
  • With an excellent Return On Equity value of 6.53%, GYRE belongs to the best of the industry, outperforming 91.12% of the companies in the same industry.
  • GYRE has a better Return On Invested Capital (6.46%) than 91.51% of its industry peers.
Industry RankSector Rank
ROA 4.17%
ROE 6.53%
ROIC 6.46%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
GYRE Yearly ROA, ROE, ROICGYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

  • GYRE has a Profit Margin of 6.20%. This is amongst the best in the industry. GYRE outperforms 89.19% of its industry peers.
  • The Operating Margin of GYRE (11.22%) is better than 91.12% of its industry peers.
  • The Gross Margin of GYRE (95.48%) is better than 95.17% of its industry peers.
Industry RankSector Rank
OM 11.22%
PM (TTM) 6.2%
GM 95.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GYRE Yearly Profit, Operating, Gross MarginsGYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GYRE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GYRE is destroying value.
  • The number of shares outstanding for GYRE has been increased compared to 1 year ago.
  • GYRE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GYRE Yearly Shares OutstandingGYRE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GYRE Yearly Total Debt VS Total AssetsGYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 8.10 indicates that GYRE is not in any danger for bankruptcy at the moment.
  • GYRE has a Altman-Z score of 8.10. This is in the better half of the industry: GYRE outperforms 79.54% of its industry peers.
  • There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.1
ROIC/WACC0.72
WACC8.92%
GYRE Yearly LT Debt VS Equity VS FCFGYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 6.19 indicates that GYRE has no problem at all paying its short term obligations.
  • GYRE has a Current ratio of 6.19. This is in the better half of the industry: GYRE outperforms 63.71% of its industry peers.
  • GYRE has a Quick Ratio of 5.64. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
  • GYRE has a better Quick ratio (5.64) than 61.20% of its industry peers.
Industry RankSector Rank
Current Ratio 6.19
Quick Ratio 5.64
GYRE Yearly Current Assets VS Current LiabilitesGYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GYRE Growth Analysis

3.1 Past

  • GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 128.26%, which is quite impressive.
  • GYRE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -43.94%.
  • Measured over the past years, GYRE shows a very strong growth in Revenue. The Revenue has been growing by 143.34% on average per year.
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%

3.2 Future

  • Based on estimates for the next years, GYRE will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.75% on average per year.
  • GYRE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.78% yearly.
EPS Next Y-40.64%
EPS Next 2Y-22.25%
EPS Next 3Y-49.4%
EPS Next 5Y16.75%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.96%
Revenue Next 5Y17.78%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GYRE Yearly Revenue VS EstimatesGYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
GYRE Yearly EPS VS EstimatesGYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

4

4. GYRE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 57.69, GYRE can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, GYRE is valued cheaper than 89.58% of the companies in the same industry.
  • GYRE is valuated expensively when we compare the Price/Earnings ratio to 25.96, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 39.39, which means the current valuation is very expensive for GYRE.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 91.70% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.04. GYRE is valued rather expensively when compared to this.
Industry RankSector Rank
PE 57.69
Fwd PE 39.39
GYRE Price Earnings VS Forward Price EarningsGYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 90.93% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 89.96% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 505.32
EV/EBITDA 41.96
GYRE Per share dataGYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • GYRE's earnings are expected to decrease with -49.40% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.25%
EPS Next 3Y-49.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GYRE Dividend Analysis

5.1 Amount

  • No dividends for GYRE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GYRE Fundamentals: All Metrics, Ratios and Statistics

GYRE THERAPEUTICS INC

NASDAQ:GYRE (3/16/2026, 8:00:02 PM)

After market: 7.5 0 (0%)

7.5

-0.05 (-0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-31
Inst Owners3.7%
Inst Owner Change5.98%
Ins Owners7.06%
Ins Owner Change0%
Market Cap681.67M
Revenue(TTM)107.27M
Net Income(TTM)6.65M
Analysts84.44
Price Target18.36 (144.8%)
Short Float %11.47%
Short Ratio14.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)194.08%
EPS beat(4)1
Avg EPS beat(4)13.67%
Min EPS beat(4)-102.82%
Max EPS beat(4)194.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.9%
Min Revenue beat(2)-14.79%
Max Revenue beat(2)-9.01%
Revenue beat(4)1
Avg Revenue beat(4)-7.84%
Min Revenue beat(4)-23.85%
Max Revenue beat(4)16.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-10.52%
EPS NQ rev (3m)6.26%
EPS NY rev (1m)0%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)-2.39%
Revenue NQ rev (3m)-2.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 57.69
Fwd PE 39.39
P/S 6.36
P/FCF 505.32
P/OCF 175.83
P/B 6.69
P/tB 7.02
EV/EBITDA 41.96
EPS(TTM)0.13
EY1.73%
EPS(NY)0.19
Fwd EY2.54%
FCF(TTM)0.01
FCFY0.2%
OCF(TTM)0.04
OCFY0.57%
SpS1.18
BVpS1.12
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.81
Profitability
Industry RankSector Rank
ROA 4.17%
ROE 6.53%
ROCE 8.39%
ROIC 6.46%
ROICexc 11.19%
ROICexgc 11.89%
OM 11.22%
PM (TTM) 6.2%
GM 95.48%
FCFM 1.26%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 110.59%
Cap/Sales 2.36%
Interest Coverage 250
Cash Conversion 27.08%
Profit Quality 20.28%
Current Ratio 6.19
Quick Ratio 5.64
Altman-Z 8.1
F-Score5
WACC8.92%
ROIC/WACC0.72
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
EPS Next Y-40.64%
EPS Next 2Y-22.25%
EPS Next 3Y-49.4%
EPS Next 5Y16.75%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.96%
Revenue Next 5Y17.78%
EBIT growth 1Y-72.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.41%
EBIT Next 3Y-66.98%
EBIT Next 5YN/A
FCF growth 1Y110.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.93%
OCF growth 3YN/A
OCF growth 5YN/A

GYRE THERAPEUTICS INC / GYRE Fundamental Analysis FAQ

What is the fundamental rating for GYRE stock?

ChartMill assigns a fundamental rating of 6 / 10 to GYRE.


Can you provide the valuation status for GYRE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Fairly Valued.


Can you provide the profitability details for GYRE THERAPEUTICS INC?

GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 5 / 10.


What is the valuation of GYRE THERAPEUTICS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 57.69 and the Price/Book (PB) ratio is 6.69.


What is the earnings growth outlook for GYRE THERAPEUTICS INC?

The Earnings per Share (EPS) of GYRE THERAPEUTICS INC (GYRE) is expected to decline by -40.64% in the next year.